JP Morgan Chase’s Oncolytics Biotech ONCY Stock Holding History

JP Morgan Chase’s Portfolio ONCY Stock Details ONCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$157	Sell	163 -1,114	-87%	-$1.03K	﹤0.01%	7513
2026 Q1	$1.03K	Buy	+1,277	New	+$1.27K	﹤0.01%	7118
2024 Q2	–	Sell	-11,500	Closed	-$12.2K	–	7643
2024 Q1	$12.2K	Hold	11,500	–	–	﹤0.01%	6316
2023 Q4	$15.5K	Buy	+11,500	New	+$18K	﹤0.01%	6309
2022 Q1	–	Sell	-36,235	Closed	-$50K	–	6889
2021 Q4	$50K	Sell	36,235 -111,238	-75%	-$206K	﹤0.01%	5945
2021 Q3	$900K	Sell	147,473 -3,200	-2%	-$7.25K	﹤0.01%	4393
2021 Q2	$919K	Buy	150,673 +94,390	+168%	+$289K	﹤0.01%	4362
2021 Q1	$214K	Buy	+56,283	New	+$168K	﹤0.01%	5121
2020 Q4	–	Sell	-16,483	Closed	-$101K	–	5846
2020 Q3	$101K	Buy	16,483 +11,200	+212%	+$20.5K	﹤0.01%	4688
2020 Q2	$10K	Buy	+5,283	New	+$9.95K	﹤0.01%	5123

Other funds holding ONCY

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Seeds Investor New York $973M AUM 33.7% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

CCM

Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return

EFG

Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return

JP Morgan Chase's ONCY Position: Q2 2026 in Review

JP Morgan Chase reduced its Oncolytics Biotech (ONCY) stake by 87% in Q2 2026, selling an estimated $1.03K and leaving 163 shares worth $157. The position accounts for ﹤0.01% of the portfolio, ranked #7513.

JP Morgan Chase first reported a position in ONCY in Q2 2020 and has held it in 10 quarters since. The position peaked at $919K in Q2 2021. 75 funds tracked by Wall St. Rank hold ONCY as of Q2 2026.

JP Morgan Chase held 163 shares of Oncolytics Biotech worth $157 as of Q2 2026.
JP Morgan Chase sold 1,114 Oncolytics Biotech shares in Q2 2026, an estimated $1.03K.
Oncolytics Biotech made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #7513 holding.
JP Morgan Chase first reported a position in Oncolytics Biotech in Q2 2020 and has held it in 10 quarters since.
JP Morgan Chase's Oncolytics Biotech position peaked at $919K in Q2 2021.
75 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.